Alembic's partner lands tentative OK for $1.4B cancer drug
NATCO's tentative approval for generic Olaparib puts Alembic in position to distribute a blockbuster, pending patent resolution.
— 8 earlier stories on Alembic Pharmaceuticals Ltd. →What's new
- NATCO received tentative USFDA approval for Olaparib tablets, generic Lynparza.
- Alembic will distribute in US; NATCO manufactures.
- Approval tentative due to ongoing Paragraph IV patent litigation.
Why this matters
The $1.4B addressable market dwarfs Alembic's current US revenues. While final approval hinges on litigation, the tentative nod materially reduces regulatory risk and puts Alembic in line for a major blockbuster opportunity once patent issues clear.
What we're watching
- Resolution of Paragraph IV litigation with AstraZeneca.
- Timing of final approval and potential launch.
- Alembic's ANDA count now 244; pipeline strength.
The full read
Alembic Pharmaceuticals took another step toward a major US launch. Partner NATCO Pharma received tentative FDA approval for generic Olaparib — a copy of AstraZeneca's Lynparza, which sold $1.4 billion in the US over the twelve months ending March 2026. The approval is tentative because of ongoing Paragraph IV patent litigation; marketing cannot begin until that is resolved. Alembic will distribute in the US, while NATCO manufactures. For context, Alembic's entire quarterly revenue is about ₹1,848 crore, making the $1.4B addressable market a multiple of current sales. The tentative nod reduces regulatory uncertainty ahead of a potential blockbuster launch. It's the company's 244th ANDA approval.
Questions answered
- What is the market size for generic Olaparib?
- The branded product Lynparza had US sales of approximately $1.4 billion in the twelve months ending March 2026, per IQVIA.
- Why is the approval 'tentative'?
- The approval is tentative due to ongoing Paragraph IV patent litigation between NATCO/Alembic and AstraZeneca. Marketing cannot begin until the litigation is resolved.
- What role will Alembic play in this product?
- Alembic will be the distributor for Olaparib in the US market, while NATCO handles manufacturing.
- How significant is this opportunity relative to Alembic's revenue?
- Alembic's latest quarterly revenue was ₹1,848 crore. The $1.4B market (approximately ₹11,700 crore annualized) represents a multiple of quarterly sales, though final market share and timing are uncertain.
- Does Alembic have other recent USFDA approvals?
- Yes, this is Alembic's 244th ANDA approval. It recently received tentative approval for Binimetinib (a $259M market) and a final nod for generic Retin-A (a $76M market).
Alembic Pharmaceuticals Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on APLLTD →- 18 Jul 2026 · 8:39 PM IST Alembic's partner lands tentative OK for $1.4B cancer drug
- 5d ago Alembic gets USFDA warning letter over ICF; facility unimpacted
- 29d ago Alembic eyes $259M cancer market with tentative US nod for Binimetinib
- 36d ago Alembic gets USFDA nod for generic Retin-A — but market is small
- 37d ago Alembic lands 180-day exclusivity shot on $91m US cancer drug